FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281982022> ?p ?o ?g. }

• W4281982022 abstract "The Huashi Baidu Formula (HSBDF), a key Chinese medical drug, has a remarkable clinical efficacy in treating acute lung injury (ALI), and it has been officially approved by the National Medical Products Administration of China for drug clinical trials. Nevertheless, the regulated mechanisms of HSBDF and its active compounds in plasma against ALI were rarely studied. Based on these considerations, the key anti-inflammatory compounds of HSBDF were screened by molecular docking and binding free energy. The key compounds were further identified in plasma by LC/MS. Network pharmacology was employed to identify the potential regulatory mechanism of the key compounds in plasma. Next, the network pharmacological prediction was validated by a series of experimental assays, including CCK-8, EdU staining, test of TNF-α, IL-6, MDA, and T-SOD, and flow cytometry, to identify active compounds. Molecular dynamic simulation and binding interaction patterns were used to evaluate the stability and affinity between active compounds and target. Finally, the active compounds were subjected to predict pharmacokinetic properties. Molecular docking revealed that HSBDF had potential effects of inhibiting inflammation by acting on IL-6R and TNF-α. Piceatannol, emodin, aloe-emodin, rhein, physcion, luteolin, and quercetin were key compounds that may ameliorate ALI, and among which, there were five compounds (emodin, aloe-emodin, rhein, luteolin, and quercetin) in plasma. Network pharmacology results suggested that five key compounds in plasma likely inhibited ALI by regulating inflammation and oxidative damage. Test performed in vitro suggested that HSBDF (0.03125 mg/ml), quercetin (1.5625 μM), emodin (3.125 μM), and rhein (1.5625 μM) have anti-inflammatory function against oxidative damage and decrease apoptosis in an inflammatory environment by LPS-stimulation. In addition, active compounds (quercetin, emodin, and rhein) had good development prospects, fine affinity, and stable conformations with the target protein. In summary, this study suggested that HSBDF and its key active components in plasma (quercetin, emodin, and rhein) can decrease levels of pro-inflammatory factors (IL-6 and TNF-α), decrease expression of MDA, increase expression of T-SOD, and decrease cell apoptosis in an inflammatory environment. These data suggest that HSBDF has significant effect on anti-inflammation and anti-oxidative stress and also can decrease cell apoptosis in treating ALI. These findings provided an important strategy for developing new agents and facilitated clinical use of HSBDF against ALI." @default.
• W4281982022 created "2022-06-13" @default.
• W4281982022 creator A5006507792 @default.
• W4281982022 creator A5011401669 @default.
• W4281982022 creator A5013959664 @default.
• W4281982022 creator A5021831026 @default.
• W4281982022 creator A5025904134 @default.
• W4281982022 creator A5036381691 @default.
• W4281982022 creator A5042194405 @default.
• W4281982022 creator A5042348933 @default.
• W4281982022 creator A5053985746 @default.
• W4281982022 creator A5057097309 @default.
• W4281982022 creator A5062755510 @default.
• W4281982022 creator A5072861069 @default.
• W4281982022 creator A5077061082 @default.
• W4281982022 creator A5078998373 @default.
• W4281982022 creator A5079594267 @default.
• W4281982022 creator A5087440723 @default.
• W4281982022 date "2022-06-02" @default.
• W4281982022 modified "2023-09-26" @default.
• W4281982022 title "Deciphering the Active Compounds and Mechanisms of HSBDF for Treating ALI via Integrating Chemical Bioinformatics Analysis" @default.
• W4281982022 cites W1993352447 @default.
• W4281982022 cites W2004921837 @default.
• W4281982022 cites W2042678771 @default.
• W4281982022 cites W2043950247 @default.
• W4281982022 cites W2054685187 @default.
• W4281982022 cites W2062830884 @default.
• W4281982022 cites W2089837509 @default.
• W4281982022 cites W2093431893 @default.
• W4281982022 cites W2103511429 @default.
• W4281982022 cites W2105261402 @default.
• W4281982022 cites W2124679671 @default.
• W4281982022 cites W2131847864 @default.
• W4281982022 cites W2142868265 @default.
• W4281982022 cites W2162011385 @default.
• W4281982022 cites W2166875189 @default.
• W4281982022 cites W2537623931 @default.
• W4281982022 cites W2538051933 @default.
• W4281982022 cites W2810919881 @default.
• W4281982022 cites W2893166720 @default.
• W4281982022 cites W2902255849 @default.
• W4281982022 cites W2984251773 @default.
• W4281982022 cites W3008090866 @default.
• W4281982022 cites W3012042308 @default.
• W4281982022 cites W3012043716 @default.
• W4281982022 cites W3015897825 @default.
• W4281982022 cites W3018409100 @default.
• W4281982022 cites W3023594261 @default.
• W4281982022 cites W3041839725 @default.
• W4281982022 cites W3042138960 @default.
• W4281982022 cites W3115114141 @default.
• W4281982022 cites W3121564771 @default.
• W4281982022 cites W3126559710 @default.
• W4281982022 cites W3134502322 @default.
• W4281982022 cites W3135797369 @default.
• W4281982022 cites W3171793506 @default.
• W4281982022 cites W3175148244 @default.
• W4281982022 cites W3185442036 @default.
• W4281982022 cites W3191097476 @default.
• W4281982022 cites W3195463592 @default.
• W4281982022 cites W3199207376 @default.
• W4281982022 cites W3203403971 @default.
• W4281982022 cites W4200503699 @default.
• W4281982022 cites W4206277095 @default.
• W4281982022 doi "https://doi.org/10.3389/fphar.2022.879268" @default.
• W4281982022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35721141" @default.
• W4281982022 hasPublicationYear "2022" @default.
• W4281982022 type Work @default.
• W4281982022 citedByCount "3" @default.
• W4281982022 countsByYear W42819820222022 @default.
• W4281982022 countsByYear W42819820222023 @default.
• W4281982022 crossrefType "journal-article" @default.
• W4281982022 hasAuthorship W4281982022A5006507792 @default.
• W4281982022 hasAuthorship W4281982022A5011401669 @default.
• W4281982022 hasAuthorship W4281982022A5013959664 @default.
• W4281982022 hasAuthorship W4281982022A5021831026 @default.
• W4281982022 hasAuthorship W4281982022A5025904134 @default.
• W4281982022 hasAuthorship W4281982022A5036381691 @default.
• W4281982022 hasAuthorship W4281982022A5042194405 @default.
• W4281982022 hasAuthorship W4281982022A5042348933 @default.
• W4281982022 hasAuthorship W4281982022A5053985746 @default.
• W4281982022 hasAuthorship W4281982022A5057097309 @default.
• W4281982022 hasAuthorship W4281982022A5062755510 @default.
• W4281982022 hasAuthorship W4281982022A5072861069 @default.
• W4281982022 hasAuthorship W4281982022A5077061082 @default.
• W4281982022 hasAuthorship W4281982022A5078998373 @default.
• W4281982022 hasAuthorship W4281982022A5079594267 @default.
• W4281982022 hasAuthorship W4281982022A5087440723 @default.
• W4281982022 hasBestOaLocation W42819820221 @default.
• W4281982022 hasConcept C185592680 @default.
• W4281982022 hasConcept C2776080593 @default.
• W4281982022 hasConcept C2778004101 @default.
• W4281982022 hasConcept C2778248515 @default.
• W4281982022 hasConcept C2781263971 @default.
• W4281982022 hasConcept C55493867 @default.
• W4281982022 hasConcept C556039675 @default.
• W4281982022 hasConcept C71924100 @default.
• W4281982022 hasConcept C98274493 @default.
• W4281982022 hasConceptScore W4281982022C185592680 @default.
• W4281982022 hasConceptScore W4281982022C2776080593 @default.

• next